AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04516265 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Video-based trunk training will apply with Theratogs
Description: Video-based trunk training will apply with Theratogs
Study NCT03069625 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sit-to-stand test
Description: CF young patients will perform 2 STS tests. Number of repetitions, cardio-respiratory response and physiological adaptations during the second test will be monitored.
Study NCT03069625 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 6-Minute Walk Test
Description: CF young patients will perform 2 6MWT tests. Number of repetitions, cardio-respiratory response and physiological adaptations during the second test will be monitored.
Study NCT04277754 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: To Observe and describe motor and visual development
Study NCT04268420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FMP013
Description: Falciparum Malaria Protein-13
Study NCT04268420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALFQ
Description: ALF with QS-21, saponin molecule derived from the tree bark of Quillaja species
Study NCT01297738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal size increase with HS
Description: On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming commercially available sugar-sweetened beverages. Subjects consume these sugar-sweetened beverages with their meals, which results in an increase in meal size.
Study NCT01297738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal frequency increase with HFHS
Description: On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming a high-fat, high-sugar liquid medical food supplement (Nutridrink®). Subjects consume the Nutridrink® 3 times a day in between meals, which results in an increase in meal frequency.
Study NCT01297738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal frequency increase with HS
Description: On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming commercially available sugar-sweetened beverages. Subjects consume these sugar-sweetened beverages 3 times a day in between meals, which results in an increase in meal frequency.
Study NCT00288431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: Different schedules and routes of administration of AP23573 will be examined. For each schedule, AP23573 + Doxorubicin will be co-administered on Day 1 of a 3-week cycle. AP23573 will be given orally and will range in dose from 10-30 mg per dose.
Study NCT00288431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: administered at 60 mg/m2 intravenously every 3 weeks
Study NCT00501748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab is a highly purified, 1328-amino acid antibody with an approximate molecular mass of 145 kD. Rituximab is a sterile, clear, colorless, preservative-free liquid concentrate for intravenous (IV) administration. Rituximab is supplied at a concentration of 10 mg/mL in either 100 mg (10 mL) or 500 mg (50 mL) single-use vials. In this single arm study all subjects are treated with two cycles of rituximab. Each cycle consists of two 1000 mg infusions administered two weeks apart. The cycles of rituximab treatment are administered at baseline and at 9 months.
Study NCT00877526 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: Subject will only fill out a questionaire when entering the observational study.
Study NCT03222180 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Website
Description: Participants in the Website condition will be provided with password-protected access to the online resource created for this trial that provides a variety of information, support and guidance that could permit them to adapt more effectively to the demands of parenting a very young child with type 1 diabetes.
Study NCT00550511 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Surgeon-performed ultrasound
Description: After clinical investigation including standardized laboratory tests the patient in the intervention arm is examined with abdominal ultrasound performed by the study surgeon.
Study NCT00867659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrotide acetate
Description: cetrotide acetate is a GnRH antagonist. The dose is 3 mg once on the day of oocyte retrieval.
Study NCT03945981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir + Lamivudine FDC
Description: Dolutegravir + Lamivudine FDC is available as white oval film-coated tablets which are packed in high density polyethylene (HDPE) bottles with induction seals and child-resistant closures. Each 60 milliliter (mL) bottle contains 30 tablets
Study NCT02610699 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional otoscope
Description: The conventional analogue otoscope will be used to provide a two-dimensional view of the ear canal. Clinicians will use this for one month periods for a total of 3 months.
Study NCT03405025 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopic ultrasound guided radiofrequency ablation
Description: To establish if radiofreuqency ablation of aldosterone producing adrenal adenomas can be carried out via the endoscopic route and to assess safety of the procedure.
Study NCT03405025 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ultrasound
Description: ultrasound
Study NCT04092309 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ACE inhibitor, Sacubitril-Valsartan
Description: Search for Protective effect after chemotherapy and bone marrow transplantation
Study NCT02610699 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone otoscope
Description: The smartphone otoscope is a pocket size smartphone attachment that uses technology and light source of a smartphone to capture reproducible images of the middle ear and tympanic membrane. Images and videos can be transmitted via real-time communication software from the device to another smartphone. Clinicians will use this for one month periods for a total of 3 months.
Study NCT01157533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Loading dose 30 mg/kg via central or peripheral intravenous infusion. Subsequent doses of vancomycin (15 mg/kg) are considered standard of care.
Study NCT03730948 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC vaccine
Description: DC vaccine for colorectal cancer
Study NCT02872636 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal catheter insertion with extracorporeal filtration of CSF
Description: Extracorporeal filtration of CSF
Study NCT03996811 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise education
Description: weekly telephone consultations concerning exercise. we discussed whether participants' exercise fulfilled the prescribed intensity, duration, or frequency and whether the participants experienced any adverse effects.
Study NCT02532686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAAOI-2
Description: 500-2000mg/d, oral, for 6 weeks
Study NCT02532686 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral, for 6 weeks
Study NCT03520257 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Apatinib
Description: Apatinib, a small molecule anti-angiogenic targeted drug that has been demonstrated to be safe and effective after failure of standard chemotherapy for advanced gastric cancer, has been initially successful in phase II clinical trials for the treatment of unresectable advanced HCC patients. The efficacy of ralfiny in the treatment of Oriental population (ORIENTAL study) is better. The randomized, double-blind, multi-center phase III clinical study of apatinib second-line treatment of advanced hepatocellular carcinoma showed a good efficacy and safety. Currently, Phase III clinical studies of apatinib in HCC patients undergoing systemic chemotherapy or sorafenib treatment have progressed. Initial results also showed good efficacy and safety.
Study NCT03520257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib, a small molecule anti-angiogenic targeted drug that has been demonstrated to be safe and effective after failure of standard chemotherapy for advanced gastric cancer, has been initially successful in phase II clinical trials for the treatment of unresectable advanced HCC patients. The efficacy of ralfiny in the treatment of Oriental population (ORIENTAL study) is better. The randomized, double-blind, multi-center phase III clinical study of apatinib second-line treatment of advanced hepatocellular carcinoma showed a good efficacy and safety. Currently, Phase III clinical studies of apatinib in HCC patients undergoing systemic chemotherapy or sorafenib treatment have progressed. Initial results also showed good efficacy and safety.
Study NCT03520257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy of tumors and portal vein tumor thrombi can promote further tumor shrinkage, and at the same time, the physiological basis for the recanalization of the original tumor thrombus itself will result in necrosis and fibrosis of the tumor thrombus, completely blocking the blood supply to the tumor portal vein. As a result, blood supply to the other side of the portal vein increases, and hepatocyte regeneration in a healthy liver is promoted, so that the patient can obtain surgical opportunities.
Study NCT03233893 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: light activated calcium silicate
Description: for the first group light activated calcium silicate can be easily placed by a 20 second light cure and ability to be syringed directly on to the cavity preparation and restore the cavity by composite restoration.~for the second group using light activated calcium hydroxide is placed by placing a disposable tip securely on to the syringe then light cure for 20 seconds depending on the light cure unit and restore the cavity with composite restoration.
Study NCT03233893 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: light activated calcium silicate
Description: for the first group light activated calcium silicate can be easily placed by a 20 second light cure and ability to be syringed directly on to the cavity preparation and restore the cavity by composite restoration.~for the second group using light activated calcium hydroxide is placed by placing a disposable tip securely on to the syringe then light cure for 20 seconds depending on the light cure unit and restore the cavity with composite restoration.
Study NCT01618448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Tolvaptan 15mg once daily
Study NCT01618448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT01458665 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional arthroscopic rotator cuff repair
Description: * Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~* The surgical area was prepared and draped with Betadine.~* Small stab incisions were made in the creation of 4-5 portals as needed.~* A scope was explored via the arthroscopic portal into the GH joint \& subacromial space.~* Repair of full thickness rotator cuff tear was done with suture anchors.~* The skin was closed with Nylon or medical staples.~* Sterile dressing was applied on surgical wound.
Study NCT01458665 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair with PRP
Description: * Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~* The surgical area was prepared and draped with Betadine.~* Small stab incisions were made in the creation of 4-5 portals as needed.~* A scope was explored via the arthroscopic portal into the GH joint \& subacromial space.~* Repair of full thickness rotator cuff tear was done with suture anchors.~* After tying sutures of the medial row, PRP gels were applied on the repair site.~* The lateral row was secured using suture anchors.~* The skin was closed with Nylon or medical staples.~* Sterile dressing was applied on surgical wound.
Study NCT00381979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Expressive Therapy
Study NCT02248987 — intervention group
Intervention type: OTHER
Intervention: patients treated with antipsychotics
Study NCT03044028 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CyMedica Orthopedics QB1 e-vive™ system
Description: a multifunctional electrotherapy device providing neuromuscular electrical stimulation (NMES), for improving quadriceps strength and improving functional outcomes accelerating functional recovery in patients managed with total knee arthroplasty (TKA).
Study NCT04534452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine HCl (Sinus Comfort, BAY112476)
Description: 30 mg Extended Release Tablets, single oral dose
Study NCT01834534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CarePartners for depression
Description: Automated telephone calls for depression monitoring and self-management support.
Study NCT02601014 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given 1 mg/kg IV
Study NCT02601014 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given 3 mg/kg IV
Study NCT02601014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: given orally per standard of care
Study NCT00619723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citicoline
Description: Citicoline is a psychostimulant/nootropic. It is an intermediate in the generation of phosphatidylcholine from choline.
Study NCT00619723 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive ingredient matching the active medication in appearance.
Study NCT00619723 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Participants will receive manual-driven Cognitive Behavioral Therapy (CBT: two sessions each week for 4 weeks followed by weekly sessions, total 16 sessions) specifically designed for persons with bipolar 1 disorder and substance abuse, and provided by a therapist with experience in CBT.
Study NCT00619723 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Participants will receive manual-driven Cognitive Behavioral Therapy (CBT: two sessions each week for 4 weeks followed by weekly sessions, total 16 sessions) specifically designed for persons with bipolar 1 disorder and substance abuse, and provided by a therapist with experience in CBT.
Study NCT03854760 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: anesthesiologist with limited experiment
Description: Using the simulate device, the trainees are going to trained and evaluated the ability of driving bronchoscopy in simulate device and clinical practice.
Study NCT04384094 — intervention group
Intervention type: DEVICE
Intervention: Esthesiometer measurement
Description: Measuring the corneal sensitivity using rebound technology.
Study NCT02696291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UV-4B 30 mg oral solution
Description: UV-4B 30 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days
Study NCT02696291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UV-4B 75 mg oral solution
Description: UV-4B 75 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days
Study NCT02696291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UV-4B 150 mg oral solution
Description: UV-4B 150 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days
Study NCT02696291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UV-4B X mg (dose to be determined) oral solution
Description: UV-4B X mg (dose to be determined) oral solution administered TID (every 8 ± 0.5 hours) for 7 days
Study NCT02696291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UV-4B Y mg (dose to be determined) oral solution
Description: UV-4B Y mg (dose to be determined) oral solution administered TID (every 8 ± 0.5 hours) for 7 days
Study NCT02696291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral solution administered TID (every 8 ± 0.5 hours) for 7 days
Study NCT02691702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB118
Description: Multiple ascending doses of BIIB118 (50 mg, 150 mg, 450 mg and 900 mg) as extemporaneously prepared solution/suspension administered once daily over 2 weeks
Study NCT02691702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Positive control used to assess the validity of DLMO as pharmacodynamic endpoint.
Study NCT02033915 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive discussion group
Description: The investigators adopt the group intervention that provide interactive discussions regarding the assessment of suicide risk among inpatients in a general hospital.
Study NCT02474745 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: - Directed open-glottis pushing
Description: Description of the intervention in the intervention group: Directed open-glottis pushing (with prolonged exhalation) must be explained to the women and professionals as follows:~After inhaling deeply, the patient will exhale while pulling in her stomach in such a way they she can use the contraction of her abdominal muscles to help the fetus descend through the birth control. She should push as long as possible~Description of the intervention in the control group: Directed closed-glottis pushing (pushing while holding one's breath) should be explained to the women and professionals as follows:~After inhaling deeply, the patient should push very hard downwards to the perineum, while holding the inhaled breath in her lungs. She should push as hard and as long as possible.
Study NCT02474745 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Directed closed-glottis pushing
Description: Description of the intervention in the intervention group: Directed open-glottis pushing (with prolonged exhalation) must be explained to the women and professionals as follows:~After inhaling deeply, the patient will exhale while pulling in her stomach in such a way they she can use the contraction of her abdominal muscles to help the fetus descend through the birth control. She should push as long as possible~Description of the intervention in the control group: Directed closed-glottis pushing (pushing while holding one's breath) should be explained to the women and professionals as follows:~After inhaling deeply, the patient should push very hard downwards to the perineum, while holding the inhaled breath in her lungs. She should push as hard and as long as possible.
Study NCT02472808 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: cTBNA without ROSE
Description: Patients will undergo conventional TBNA and endobronchial biopsy and transbronchial lung biopsy
Study NCT03660995 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of language skills and procedural learning of children with SLI and their controls. DNA sampling.
Description: Behavioral evaluation of language skills at the formal, semantic and pragmatic levels and of procedural learning for each child with SLI and each control child.~DNA sampling for each child.
Study NCT03660995 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluation of language skills and procedural learning of children with SLI and their controls. DNA sampling.
Description: Behavioral evaluation of language skills at the formal, semantic and pragmatic levels and of procedural learning for each child with SLI and each control child.~DNA sampling for each child.
Study NCT03280810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Movement group
Description: Experimental group : patients with schizophrenia who realise psycho-corporal training once a week, during 1 hour and a half for a period of two months
Study NCT03606785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid Injection
Description: The TA group will receive an intravenous bolus of (10 mg/kg) in 100 ml of normal saline over 20 minutes after induction of anesthesia and before surgical incision
Study NCT03606785 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo injection
Description: patients will receive a placebo of 100 mL 0.9% normal saline
Study NCT01149863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Plerixafor 240 mcg/kg SC will be administered daily starting on the first day of stem cell apheresis, up to a total of 4 doses.
Study NCT02676882 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: EnBrace HR
Description: Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 12 week study
Study NCT03617666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Patients with newly diagnosed cHL will receive 4 doses of single agent avelumab 10 mg/kg intravenously given every 2 weeks.
Study NCT01772329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy
Description: CT will be used as a preemptive treatment in an effort to minimize the effects of catastrophic thinking.
Study NCT01772329 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine Care
Description: Routine Care. No Cognitive Therapy Intervention
Study NCT01482416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogens, Conjugated (USP)
Description: Experimental group will use 0.625mg/day during 30 days